Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
26S proteasome non-ATPase regulatory subunit 11 (PSMD11)
- Target
- PSMD11
- Molecular classification
- Proteasome subunit, Enzyme complex component, Ubiquitin-proteasome system, Other
01
Overview
26S proteasome non-ATPase regulatory subunit 11 (PSMD11) is a non-ATPase subunit of the 19S regulatory "lid" of the 26S proteasome complex, a multiprotein machinery responsible for ATP-dependent degradation of ubiquitinated proteins in eukaryotic cells. PSMD11 is essential for proteasome assembly and overall proteolytic activity, impacting processes such as cell cycle progression, apoptosis, DNA repair, antigen presentation, and regulation of circadian clock activity via control of negative regulators' stability and nuclear translocation. Aberrant PSMD11 expression has been associated with tumorigenesis and may influence immune and cancer cell biology, making it a candidate diagnostic/prognostic and therapeutic target, particularly in oncology.
- Other names
- 26S proteasome regulatory subunit Rpn626S proteasome regulatory subunit S926S proteasome regulatory subunit p44.5S9p44.5MGC3844Rpn6PSMD11
02
Mechanism of action
Inhibition of proteasome-mediated proteolysis (blocks degradation of ubiquitinated proteins, affecting cell cycle, apoptosis, and immune evasion pathways)
03
Biological functions
Protein degradation (ATP-dependent ubiquitin-proteasome pathway)Regulation of cellular protein homeostasisCell cycle regulationApoptosisDNA damage repairRegulation of the circadian clock via post-translational modification and nuclear/cytoplasmic transport of repressor proteinsAntigen processing for MHC class I presentation
04
Disease associations
Cancer (including lung adenocarcinoma, hepatocellular carcinoma, pancreatic cancer)Neurodegenerative diseases (by analogy with proteasome impairment disorders)Other
05
Safety considerations
Potential for widespread cellular toxicity if proteasome function is suppressedEffects on normal tissue homeostasis, immune surveillance, and circadian regulationResistance and compensatory cellular adaptation when targeting proteasome function in cancer therapy
06
Interacting drugs
Bortezomib (and other proteasome inhibitors; these primarily target the proteasome complex generically, but can affect PSMD11 function as part of the 26S proteasome)
07
Biomarkers
PSMD11 expression may serve as a prognostic biomarker in cancers such as lung adenocarcinoma, hepatocellular carcinoma, and pancreatic cancer
Beyond the preview
Go deeper on 26S proteasome non-ATPase regulatory subunit 11 (PSMD11).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 26S proteasome non-ATPase regulatory subunit 11 (PSMD11).